CCBR – SYNARC Reorganizes to Enhance Scientific and Service Excellence in Clinical Trials
COPENHAGEN / SAN FRANCISCO, CA. – June 6, 2008.
CCBR – SYNARC, the world's leading provider of centralized imaging, molecular marker analyses and multinational clinical research facilities to the pharmaceutical and biotechnology industry, announced today a major change in its capital structure, led by a Group of Danish investors, including Nordic Bioscience A/S and Den Danske Forskningsfond.
Following this transaction, Mr. Hervé Girsault has been appointed as Chief Executive Officer of the company. Mr. Girsault brings more than 10 years of experience in the Pharmaceutical and biotech industry primarily acquired at Novartis where he held the position of General Manager of Novartis in the Benelux and senior positions in Merger and Acquisition and Business Development in Basel Headquarters. Prior to joining Novartis, Mr. Girsault was the General Manager of Gerber Products Company in Europe.
Furthermore, a new Board of Directors has been elected which includes two of the original founders of Synarc, Dr Claus Christiansen (Chairman) and Dr. Harry K. Genant, and Mr. Henrik B. Sanders, a partner at Mazanti-Andersen & Partners, a law firm based in Copenhagen.
“This is a defining moment in CCBR-SYNARC history as we intensify our commitment to providing the highest standards of scientific excellence in clinical research” said Claus Christiansen. “Passionate scientists are the key to this effort, and this reorganization puts them back at the center of our corporate strategy.”
“Attracting leading scientific talent and providing them with compelling opportunities to use their expertise in applied science has always been the strategy at CCBR – SYNARC said Harry Genant. This change allows us to intensify and expand those efforts long-term as we move towards a more complete and diversified applied sciences organization, one which is dedicated to facilitating and enhancing new drug development for the pharmaceutical and biotechnology industries.”
Hervé Girsault added, “CCBR - SYNARC is currently the premier provider of high-end central imaging analyses and clinical research facilities for clinical trials in the world. I am looking forward to working with such a talented and accomplished group to further enhance the quality and the scope of our Services to our Pharmaceutical and Biotech Partners to help them bring their novel medicines to market in a timely, reliable and cost efficient manner.”
CCBR -SYNARC is a leader in providing advanced central imaging analysis, molecular markers and clinical research facilities enabling pharmaceutical, biotechnology and medical device industry clients to accelerate clinical trials, enhance the likelihood of success and reduce the cost of developing novel therapies. CCBR - SYNARC currently manages more than 150 clinical trials, involving more than 100,000 patients at 2,500 sites worldwide. CCBR - SYNARC operates out of offices in eleven countries, including in the US, Denmark, France, Germany, Poland, the Czech Republic, Romania, Lithuania and Estonia in Europe, Brazil in South America, and Hong Kong and Beijing in China.
# # #
Media Contact:
Victoria Swanson
415 817-7912
victoria.swanson@synarc.com
